Benchimol A, Desser K B
Postgrad Med. 1981 Jan;69(1):77-84. doi: 10.1080/00325481.1981.11715649.
The new and potent antiarrhythmic drugs herald an exciting era in the treatment of cardiac arrhythmias. Encainide, tocainide, and mexiletine are effective in treating acute and chronic ventricular arrhythmias. Verapamil promises to be the drug of choice for paroxysmal supraventricular tachycardia. Acetubolol provides the advantages of selective beta receptor blockade and has minimal influence on pulmonary function. Aprindine and amiodarone block conduction in accessory pathways and are very suitable for treating tachycardias associated with Wolff-Parkinson-White syndrome. Ethmozin is a phenothiazine derivative with potent antiarrhythmic effects. Many of these new agents are being used with striking success abroad and at specialized treatment centers for experimental research in the United States.
新型强效抗心律失常药物开创了心律失常治疗的激动人心的时代。恩卡胺、妥卡胺和美西律对治疗急慢性室性心律失常有效。维拉帕米有望成为阵发性室上性心动过速的首选药物。醋丁洛尔具有选择性β受体阻滞的优点，对肺功能影响极小。阿普林定和胺碘酮可阻断旁路传导，非常适合治疗与预激综合征相关的心动过速。乙吗噻嗪是一种具有强效抗心律失常作用的吩噻嗪衍生物。这些新型药物中有许多在国外以及美国的专业治疗中心用于实验研究时都取得了显著成功。
